VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

Processa Pharmaceuticals, Inc. has announced a licensing agreement with Intact Therapeutics for PCS12852, a novel 5-HT4 receptor agonist aimed at treating gastroparesis and gastrointestinal motility ...

Webcast Link: https://www.webcaster4.com/Webcast/Page/3023/49969 Mr. Ng will be available for one-on-one meetings throughout the conference. Investors can attend the ...

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a ...

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of ...

The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on September 2, 2025. The analyst firm set a price target for $1.00 expecting PCSA to fall to ...

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the ...

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Processa Pharmaceuticals Inc. company and executive profile by Barron's. View the latest PCSA company infomation and executive bios.